FDA advisors strongly back new Alzheimer's drug, despite risks and limitations

from www.npr.org 2 weeks ago

Donanemab, if approved, would have advantages over Leqembi with a monthly dosing that can be halted for some patients.
www.npr.orghttps://www.npr.org/sections/shots-health-news/2024/06/10/g-s1-3818/fda-advisors-back-alzheimer-drug-donanemab-despite-risks

Read at www.npr.org

#alzheimers-drug #fda-approval #donanemab #leqembi #disease-progression

[

]

[

...

]

FDA advisors strongly back new Alzheimer's drug, despite risks and limitationsFDA advisors strongly back new Alzheimer's drug, despite risks and limitations Briefly

FDA advisors strongly back new Alzheimer's drug, despite risks and limitations
FDA advisors strongly back new Alzheimer's drug, despite risks and limitations
Briefly